UBR7 in concert with EZH2 inhibits the TGF-β signalling leading to extracellular matrix remodelling [ChIP-seq]
ChIP-seq / ATAC-seq (genome binding and open chromatin) · human · 14 samples
- What it is
- ChIP-seq / ATAC-seq (genome binding and open chromatin)Where proteins bind the genome, or which regions are open and active.
- Organism
- Homo sapiens (human)
- Topic
- Breast cancerThis series is part of our curated briefing on it.
- Samples
- 14 samples: 7 conditions, mostly in duplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE262487_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Look for peak files (.bed, .narrowPeak) and signal tracks (.bigWig) among the supplementary files; the raw reads are on ENA.
Also filed as BioProject PRJNA1107816 and SRA study SRP506827. Searching any of these in the dataset finder brings you back here.
Supports a case/control comparison: 4 samples read as cases, 8 as controls.
How we read this: 7 replicated groups read from 14 sample titles; they account for 14 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8252264 Scrambled Input / Whole Cell Extract DNA_REP1 Scrambled Input / Whole…
- GSM8252265 Scrambled Input / Whole Cell Extract DNA_REP2 Scrambled Input / Whole…
- GSM8252266 UBR7 silenced cells Input / Whole Cell Extract DNA_REP1 UBR7 silenced cells Inp…
- GSM8252267 UBR7 silenced cells Input / Whole Cell Extract DNA_REP2 UBR7 silenced cells Inp…
- GSM8252268 Chromatin Immunoprecipitate of H3k27Ac from Wildtype Cells_REP1 Chromatin Immunoprecipi…
- GSM8252269 Chromatin Immunoprecipitate of H3k27Ac from Wildtype Cells_REP2 Chromatin Immunoprecipi…
- GSM8252270 Chromatin Immunoprecipitate of H3k27Me3 from Wildtype Cells_REP1 Chromatin Immunoprecipi…
- GSM8252271 Chromatin Immunoprecipitate of H3k27Me3 from Wildtype Cells_REP2 Chromatin Immunoprecipi…
- GSM8252272 Chromatin Immunoprecipitate of H3k27Ac from UBR7 Mutant Cells_REP1 Chromatin Immunoprecipi…
- GSM8252273 Chromatin Immunoprecipitate of H3k27Ac from UBR7 Mutant Cells_REP2 Chromatin Immunoprecipi…
- GSM8252274 Chromatin Immunoprecipitate of H3k27Me3 from UBR7 Mutant Cells_REP1 Chromatin Immunoprecipi…
- GSM8252275 Chromatin Immunoprecipitate of H3k27Me3 from UBR7 Mutant Cells_REP2 Chromatin Immunoprecipi…
- GSM8252276 Chromatin Immunoprecipitate of UBR7 from Wildtype Cells_REP1 Chromatin Immunoprecipi…
- GSM8252277 Chromatin Immunoprecipitate of UBR7 from Wildtype Cells_REP2 Chromatin Immunoprecipi…
- GSE104193 Hypoxia-mediated translational activation of ITGB3 in breast cancer cells enhances TGF-β signalling and malignant features in vitro and in vivo 32 samples same disease briefing · shares tgf
- GSE10885 An integromic analysis reveals that metaplastic carcinomas are distinct from basal-like tumors. 244 samples same disease briefing
- GSE10886 A Supervised Risk Predictor of Breast Cancer Based on Biological Subtypes 226 samples same disease briefing
- GSE11121 The humoral immune system has a key prognostic impact in node-negative breast cancer 200 samples same disease briefing
- GSE104675 Role for the Transcriptional Activator ZRF1 in Breast Cancer Progression and Endocrine Resistance 6 samples same disease briefing
- GSE302321 Co-targeting EZH2 and TEAD elicits apoptosis through tumor-intrinsic innate immune signaling in Hippo pathway-mutated cancers - ChIP-seq data from genetic disruption of EZH2 41 samples shares ezh2, chip-seq
- GSE212437 EZH2 reads DNA 6mA to regulate survival and drug resistance of human head and neck squamous carcinoma by suppressing RIOX2-CDKN1A-NRF2 signaling axis [MeDIP-ChIP-seq-shRNA] 17 samples shares ezh2, chip-seq
- GSE252382 ATACseq of TNBC cell lines treated with EZH2i (tazemetostat) and/or AKTi (ipatasertib) 84 samples shares ezh2
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.